Advanced SearchSearch Tips
The Effects of Transcranial Electric Stimulation and Cognition Reinforcement Training on the Expression of Tau Protein in Alzheimer's Disease Rat Models
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
The Effects of Transcranial Electric Stimulation and Cognition Reinforcement Training on the Expression of Tau Protein in Alzheimer's Disease Rat Models
Ryu, Sung Hoon; Min, Kyung Ok; Sim, Ki Cheol; Kim, Gi Do; Kim, Gye Yeop;
  PDF(new window)
This study is intended to examine the tDCS and Morris Water maze training in Alzheimer's disease(AD) rats on Tau protein expression. Experiment groups were divided into four groups and assigned 16 rats to each group. Group I was a control group(AD induced by scopolamine); Group II was a experimental control group(AD injured by scopolamine and treatment tacrine); Group III was a group of tDCS application after AD injured by scopolamine; Group IV was a group of morris water maze training after AD injured by scopolamine. In cognition test, the outcome of group II was significantly lower than the groups(p<.001). and group III, IV were significantly low result at 14 days(p<.05). In histological finding, the experimental groups were destroy of micro vessels and finding of cell atropy and swelling. Group III, IV were decreased in degeneration of liver and kidney cells. In immuno- histochemistric response of BDNF and tau protein in hippocampus, BDNF expression of Group II was more increase than the other groups. and increase of BDNF expression was III, IV were higher than group I at 21 days. Tau protein expression of Group II was more decrease than the other groups. and decrease of Tau protein expression was III, IV were lower than group I at 21 days. These result suggest that improved tDCS and morris water maze training after scopolamine induced is associated with dynamically altered expression of BDNF and Tau protein in hippocampus and that is related with cognitive function.
Alzheimer's Disease;tDCS;Morris Water Maze Training;Tau;
 Cited by
Schilling S, Zeitschel U, Hoffmann T, Heiser U, Francke M, Kehlen A. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzhemer's disease-like pathology. nature medicine 2008; 14(10): 1106-1111. crossref(new window)

Wheatley R. Nursing management of the patient undergoing stereotactic surgery. Br J Theatre Nurs 1995; 5(5): 5-9.

Cummings JL, Vinters HV, Cole GM, Khachaturian ZS. Alzheimer's disease etiologies, pathophysiology, cognitive reserve and treatment opportunities. Neurology 1998; 51: 2-17. crossref(new window)

Carter LT, Howard BE, O'Neil WA. Effectiveness of cognitive skill remediation in acute stroke patients. Am J Occup Ther 1983; 37(5): 320-326. crossref(new window)

Liebetanz D, Nitsche MA, Tergau F, Paulus W. Pharmacological approach to the mechanisms of transcranial DC-stimulation-induced aftereffects of human motor cortex excitability. Brain 2002; 125(10): 2238-2247. crossref(new window)

Baudewig J, Nitsche MA, Paulus W, Frahm J. Regional modulation of BOLD MRI responses to human sensorimotor activation by transcranial direct current stimulation. Magnetic Resonance in Medicine 2001; 45(2): 196-201. crossref(new window)

Nitsche MA, Paulus W. Sustained excitability elevations induced by transcranial DC motor cortex stimulation in humans. Neurology 2001; 57(10): 1899-1901. crossref(new window)

Nitsche MA, Liebetanz D, Lang N, Antal A, Tergau F, Paulus W. Safety criteria for transcranial direct current stimulation (tDCS) in humans. Clinical Neuro physiology 2003; 114(11): 2220-2222.

Stagg CJ, Best JG, Stephenson MC, O'She J, Wylezinska M, Kincses ZT, Morris PG, Matthews PM, Johansen-Berg H. Polarity-sensitive modulation of cortical neuro- transmitters by transcranial stimulation. Journal of Neuroscience 2009; 29(16): 5202-5206. crossref(new window)

Mulder T. A process-oriented model of human motor behavior: toward a theory-based rehabilitation approach. Physical therapy 1991; 71(2): 157-164. crossref(new window)

Gould E, Beylin A, Tanapat P, Reeves A, Shors TJ. Learning enhances adult neurogenesis in the hippocampal formation. Nature Neuroscience 1999; 2(3): 260-265. crossref(new window)

Goodwin VA, Richards SH, Taylor RS, Taylor AH, Campbell JL. The effectiveness of exercise interventions for people withParkinson's disease: a systematic review and meta-analysis. Movement Disorders 2008; 23(5): 631-640. crossref(new window)

Isaksson J, Hillered L, Olsson Y. Cognitive and histopathological outcome after weight-drop brain injury in the rat: influence ofsystemic administration 2001; 102(3): 246-256.

Jolkkonen J, Gallaghe.r NP, Zilles K, Silvenius J. Behavioral deficits and recovery following transient focal ischemia in rats: glutamatergic and GABAergic receptor densities. Behavioural Brain Research 2003; 138(2): 187-200. crossref(new window)

Sinson G, Perri B, Trojanowski J, Flamm E, McIntosh T. Improvement of cognitive deficits and increased cholinergic neuronal loss and apoptotic cell death following neurotrophin infusion after experimental traumatic brain injury. Journal Neurosurgery 1997; 86(3): 511-518. crossref(new window)

Gong CX, Igba K. Hyperphosphorylation of microtubules-associated protein tau: A promising therapeutic target for Alzheimer's disease. Current medicinal Chemistry 2008; 15(23): 2121-2328.

Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forester C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005; 15(309): 476-481.

Drechse DN, Hyman AA, Cobb MH, Kirschner MW. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein Tau. Molecular Biology of the Cell 1992; 3(10): 1141-1154. crossref(new window)

Ionso AD, Grundkelqbal I, Iqubal K. Alzheime's disease Hyperphosphorylated Tau sequesters normal Tau into tangles of filaments and disassembles microtubules. Nature Medicine 1996; 2(7): 783-787. crossref(new window)

Kim SJ. Mechanism of Motor Recovery Induced by Repeated Transcranial Direct Current Stimulation in Stroke Rat Model. Department of Rehabilitation Medicine The Graduate School Seoul National University. 2009.

Nowak DA, Grefkes C, Amei M, Fink GR. interhemispheric Competition After Stroke: Brain Stimulation to Enhance Recovery of Function of the Affected Hand. Neurorehabilitation and Neural Repair 2009; 23(7): 641-656. crossref(new window)

Erickson KI, Voss MW, Prakash RS, Basak C, Szabo A, Chaddoc L. Exercise training increases size of hippocampus and improves memory. Proceedings of the National Academy of Sciences of the United States of America 2011; 108(7): 3017-3022. crossref(new window)

Fuchs E, Gould E. Mini-review: in vivo neurogenesis in the adult brain: regulation and functional implications. European journal of Neuroscience 2000; 12(7): 2211-2214. crossref(new window)

Zola-Morgan S, Squire LR, Rempel NL, Clower RP, Amaral DG. Enduring memory impairment in monkeys after ischemic damage to the hippocampus. J Neurosci 1992; 12: 2582-2596.

Onodera H, Araki T, Kogure K. Protein kinase C activity in the rat hippocampus after forebrain ischemia : auto-radiographic analysis by phorbol 12, 13-dibutyrate. Brain Res 1989; 481: 1-7. crossref(new window)

Spieker EA, Astur RS, West JT, Griego JA, Rowland LM. Spatial memory deficits in a virtual reality eight-arm radial maze in schizophrenia. Schizophr Res 2011; 1-6.

Baker JM, Rorden C, Fridriksson J. Using transcranial direct-current stimulation to treat stroke patients with aphasia. Stroke 2010; 41(6): 1229-1236. crossref(new window)

Um HS, Kang EB, Leem YH, Cho IH, Yang CH, Chae KR, Hwang DY, Cho JY. Exercise training acts as a therapeutic strategy for reduction ofthe pathogenic phenotypes for Alzheimer's disease in an NSE/APPsw-transgenic model. International Journal Molecular Medicine 2008; 22: 529-539.

Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, Jeffreys M, Hyde C. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. Health Technol Assess 2012; 16(21): 1-470.